Timber Pharmaceuticals Announces Closing of Exercise of Underwriter’s Option to Purchase Additional Common Stock
November 09 2021 - 4:05PM
via NewMediaWire -- Timber Pharmaceuticals, Inc.
(“Timber” or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic
diseases, today announced that the underwriter of its previously
announced underwritten public offering which closed on November 5,
2021 has exercised in full the remainder of its option to purchase
an additional 3,515,625 shares of its common stock at the public
offering price, less underwriting discounts and commissions. After
giving effect to the sale of 3,515,625 additional shares pursuant
to the exercise of the option, the total number of shares of common
stock (or common stock equivalents) sold by the Company in the
offering increased to 26,953,125, together with warrants to
purchase up to 26,953,125 shares of common stock issued at the
closing on November 5, 2021, for total gross proceeds of $17.25
million before deducting underwriting discounts and commissions and
other offering expenses.
H.C. Wainwright & Co. acted as the sole
book-running manager for the offering.
Timber intends to use the net proceeds from the
offering for general corporate purposes, including, but not limited
to, ongoing research and pre-clinical studies, clinical trials, the
development of new biological and pharmaceutical technologies,
investing in or acquiring companies that are synergistic with or
complementary to the Company’s technologies, and licensing
activities related to the Company’s current and future product
candidates and working capital.
A shelf registration statement on Form S-3 (File
No. 333-255743) relating to the securities offered was filed with
the U.S. Securities and Exchange Commission (the “SEC”) on May 4,
2021, and became effective on May 11, 2021. The offering was
made only by means of a prospectus supplement and accompanying
prospectus that form a part of the shelf registration
statement. A final prospectus supplement and
accompanying prospectus relating to the offering have been filed
with the SEC and are available on the SEC’s website, located
at www.sec.gov. Electronic copies of the final prospectus
supplement and accompanying prospectus relating to the offering may
also be obtained from H.C. Wainwright & Co., LLC, 430
Park Avenue, New York, NY 10022, by email
at placements@hcwco.com or by phone at (212)
856-5711.
This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Timber Pharmaceuticals,
Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic
diseases. The Company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and other sclerotic skin diseases. For
more information, visit www.timberpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to Timber’s
expectations regarding future financial and/or operating results,
the use of net proceeds from the public offering, potential for our
products and future revenues or growth in this press release
constitute forward-looking statements.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors, such as
market and other conditions, which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in the Company's Annual Report on Form 10-K for the year
ended December 31, 2020 as well as other documents filed by the
Company from time to time thereafter with the Securities and
Exchange Commission. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law.
For more information,
contact:
Timber Pharmaceuticals, Inc. John
Koconis Chairman and Chief Executive
Officerjkoconis@timberpharma.com
Investor Relations:Stephanie PrincePCG
Advisory(646) 863-6341sprince@pcgadvisory.com
Media Relations:Adam DaleyBerry & Company
Public Relations(212) 253-8881adaley@berrypr.com
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024